Janux Therapeutics, Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Janux Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $1.65M, a 842.29% increase year-over-year.
- Janux Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $3.54M, a 293.45% increase year-over-year.
- Janux Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-12-31 was $2.50M, a 69.21% decline year-over-year.
- Janux Therapeutics, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $493.00K, a 70.10% decline year-over-year.
- Janux Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2025 was $4.07M, a 71.29% decline from fiscal 2024.
- Janux Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2024 was $14.18M, a 531.17% increase from fiscal 2023.
- Janux Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2023 was $2.25M, a 224500.00% increase from fiscal 2022.
- Janux Therapeutics, Inc. stock issued during period, value, stock options exercised for fiscal 2022 was $1.00K, a 95.00% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $1.65M 10-Q · filed 2026-08-06 | $8.19M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $3.54M 10-Q · filed 2026-05-07 | $6.71M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $2.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $4.07M 10-K · filed 2026-02-26 |
| 2025-09-30 | $493.00K 10-Q · filed 2025-11-06 | $9.69M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $175.00K 10-Q · filed 2026-08-06 | $10.85M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $901.00K 10-Q · filed 2026-05-07 | $13.42M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $8.12M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $14.18M 10-K · filed 2026-02-26 |
| 2024-09-30 | $1.65M 10-Q · filed 2025-11-06 | $6.64M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $2.75M 10-Q · filed 2025-08-07 | $5.07M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $1.66M 10-Q · filed 2025-05-08 | $2.32M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $587.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $2.25M 10-K · filed 2026-02-26 |
| 2023-09-30 | $79.00K 10-Q · filed 2024-11-06 | $1.66M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $1.58M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $1.58M 10-Q · filed 2024-05-08 | $1.58M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $1.00K 10-K · filed 2025-02-27 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $1.00K derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $1.00K derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $1.00K 10-Q · filed 2023-05-09 | $1.00K derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-10 | $20.00K 10-K · filed 2023-03-10 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $32.00K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $32.00K derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $20.00K 10-Q · filed 2022-05-10 | |
| 2020-12-31 | $12.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-18 | $16.00K 10-K · filed 2022-03-18 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |